Tozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions. These trials include NCT03096795 (completed; healthy participants, COPD... These trials include NCT03096795 (completed; healthy participants, COPD patients, and healthy Japanese participants), NCT05070312 (completed; healthy Chinese participants), NCT04212169 (completed with results; atopic dermatitis), NCT04631016 (completed; COPD and chronic bronchitis), NCT04570657 (completed with results; moderate-to-severe...
- Mechanism
- Curator reviewed
MEDI3506 is an IL-33 monoclonal antibody investigated for the treatment of diabetic kidney disease.
- Also known as
- Immunoglobulin G1-lambda2, anti-[Homo sapiens IL33 (interleukin 33, DVS27, NF-HEV, IL1F11)], monoclonal antibody; gamma1 heavy chain (1-456) [VH (Homo sapiens IGHV3-23*01 (93.9%) -(IGHD) -IGHJ4*01 (85.7%) L123>M (121)) CDR-IMGT [8.8.19] (26-33.51-58.97-1 · Immunoglobulin G1, anti-(human interleukin 33) (human monoclonal MEDI3506 γ1-chain), disulfide with human monoclonal MEDI3506 λ-chain, dimer
- Code names
- MEDI-3506
Resolves to
What you can answer from here — as of February 22, 2026
Which drugs share a target with Tozorakimab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account